All Posts Tagged With: "MDVN"
(DNDN) Dendreon’s Provenge Showing Bleak Outlook
Dendreon Corporation (DNDN) reported fourth-quarter 2011 earnings (including stock-based compensation expense but excluding other special items) of 37 cents per share, in contrast to the Zacks Consensus Estimate...
(MDVN) Medivation Incorporated – Bull of the Day
Medivation, Inc. (MDVN) shares received a major boost recently with the company and its partner, Astellas, reporting impressive data on MDV3100 from a pre-specified interim analysis of a phase III study,...
(DNDN) Dendreon Loss Narrows
Dendreon Corporation (DNDN) reported third-quarter 2011 loss (including stock-based compensation expense but excluding other special items) of 67 cents per share, which was narrower than the Zacks Consensus...
(DNDN) Dendreon Analyst Maintains Neutral on Shares
We have maintained a Neutral rating on Dendreon Corporation (DNDN) with a target price of $13 per share after appraisal of the second quarter 2011 results.
Dendreon Corporation reported weaker-than-expected...
(DNDN) Medicare to Cover Dendreon’s Provenge
Dendreon Corporation (DNDN) has of late been announcing significant milestones, related to its potential blockbuster cancer vaccine Provenge. Most recently, the company announced that the Centers for Medicare...
(DNDN) Dendreon Gets FDA Clearance on Second Facility
Dendreon Corporation (DNDN) recently received clearance from the U.S. Food and Drug Administration (FDA) to expand manufacturing facility for its cancer vaccine Provenge, in the U.S. The company’s Los Angeles...
(BOBE) Company News for May 11, 2011 – Corporate Summary
• Microsoft Corp. (NASDAQ:MSFT) will purchase internet communications leader Skype from the investor consortium led by Silver Lake. The deal which is worth $8.5 billion in cash has been approved by the boards of directors...
(JNJ) Johnson and Johnson Earns FDA Approval for Cancer Drug
Johnson and Johnson (JNJ) recently announced US Food and Drug Administration (FDA) approval for its prostate cancer therapy, Zytiga (abiraterone acetate). Zytiga, an oral, once-daily medication, gained approval...
(MNKD) Why Phase II is the Sweet Spot for Biotech Investing
by Marc Lichtenfeld, Investment U’s Healthcare Expert
Wednesday,...
(DNDN) Dendreon Learns Medicare May Pay for Provenge Prostate Cancer Vaccine
Dendreon Corporation (DNDN) received a huge boost today when the Centers for Medicare and Medicaid Services (CMS) proposed to pay for its lead prostate cancer vaccine Provenge.
Provenge was approved...
(DNDN) Dendreon Analyst Maintains Neutral Rating on Shares
We have maintained our Neutral recommendation on Dendreon Corporation (DNDN) with a target price of $39.00 following the announcement of fourth quarter and full year 2010 financial results.
Dendreon’s...
(MDVN) Medivation Analyst Reiterates Neutral Rating
We recently reiterated our Neutral recommendation on biopharmaceutical company Medivation Inc. (MDVN). Medivation, which currently does not have any marketed product in its portfolio, focuses on the development...
(MDVN) Medivation 2010 Second Quarter Earnings Narrow Loss
Medivation Inc. (MDVN) reported a loss of 21 cents per share in the second quarter of 2010, narrower than the Zacks Consensus Estimate of a loss of 36 cents and the year-ago loss of 29 cents. Lower expenses...
(MDVN) Medivation Quarterly Report Shows Wider Loss
Medivation Inc. (MDVN) reported a loss of 51 cents per share in the first quarter of 2010, exceeding the Zacks Consensus Estimate of a loss of 42 cents and the year-ago loss of 19 cents. Lower revenues and...
(MDVN) Medivation Announces Workforce Reductions
Medivation, Inc. (MDVN) recently announced that it intends to reduce its workforce by 20% or 23 people to save costs and focus its resources towards research and development activities related to dimebon...
(MDVN) Medivation Reports Wider Fourth Quarter Loss
Medivation Inc. (MDVN) reported dismal results in the fourth quarter of 2009 with net loss coming in at 78 cents per share, wider than the Zacks Consensus Estimate of a net loss of 57 cents and the year-ago...
(MDVN) Medivation Shares Fall on Alzheimer’s Phase III Data
Medivation, Inc. (MDVN) shares fell 67% following the release of disappointing phase III results on lead pipeline candidate dimebon. The company, along with partner Pfizer, Inc. (
4Mar2010 | vitalstocks | 0 comments | Continued($JPM) JP Morgan Healthcare Conference in San Francisco
by Marc Lichtenfeld, Healthcare Expert
Wednesday, January 13, 2010: Issue...
(MDVN) Medivation Incorporated Starts New Alzheimer’s Trials
Earlier this month, Medivation, Inc. (MDVN) and Pfizer, Inc. (PFE) initiated two phase III studies, CONTACT and CONSTELLATION, with Dimebon...
(MDVN) Medivation’s Earnings Report Lags Expectations
Medivation Inc. (MDVN) has reported a net loss of 42 cents per share in the third quarter of 2009, exceeding the Zacks Consensus Estimate of a net loss of 39 cents. However,...
(MDVN) Three Ways to Stop Making Emotional Investment Decisions
by Marc Lichtenfeld, Advisory Panelist
“You think they’re your...